Weintraub Michael
CIK: 0001776800
Associated companies
Transaction History
| PHR | ▼ Sell | Open Market | 10,000 | $300K | 8/25/2025 | View on chart |
| PHR | ▲ Buy | Option Exercise | 3,113 | $25K | 8/25/2025 | View on chart |
| PHR | ▲ Buy | Option Exercise | 6,887 | $32K | 8/25/2025 | View on chart |
| PHR | ▲ Buy | Grant | 6,700 | $185K | 6/25/2025 | View on chart |
| PHR | ▲ Buy | Option Exercise | 2,569 | $12K | 6/10/2025 | View on chart |
| PHR | ▼ Sell | Open Market | 2,569 | $72K | 6/10/2025 | View on chart |
| PHR | ▲ Buy | Option Exercise | 7,431 | $35K | 6/9/2025 | View on chart |
| PHR | ▼ Sell | Open Market | 7,431 | $204K | 6/9/2025 | View on chart |
| PHR | ▲ Buy | Option Exercise | 861 | $4K | 12/16/2024 | View on chart |
| PHR | ▼ Sell | Open Market | 861 | $22K | 12/16/2024 | View on chart |
| PHR | ▼ Sell | Open Market | 20,565 | $515K | 12/13/2024 | View on chart |
| PHR | ▲ Buy | Option Exercise | 20,565 | $97K | 12/13/2024 | View on chart |
| PHR | ▲ Buy | Option Exercise | 18,574 | $87K | 12/11/2024 | View on chart |
| PHR | ▼ Sell | Open Market | 18,574 | $466K | 12/11/2024 | View on chart |
| PHR | ▲ Buy | Option Exercise | 15,152 | $31K | 12/2/2024 | View on chart |
| PHR | ▼ Sell | Open Market | 15,152 | $318K | 12/2/2024 | View on chart |
| PHR | ▲ Buy | Grant | 8,490 | $0 | 6/26/2024 | View on chart |
| PHR | ▲ Buy | Grant | 6,051 | $0 | 6/28/2023 | View on chart |
| PHR | ▲ Buy | Grant | 7,397 | $0 | 6/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Barclays Raises Phreesia Price Target to $11
Barclays has raised its price target for Phreesia to $11 while maintaining an Equal-Weight rating. This update places the firm's outlook within the broader analyst consensus, which currently averages $14.13. The stock remains well below its 52-week high of $24.07, reflecting a significant drop from previous levels.
Barclays Raises Phreesia Price Target to $11. Barclays has raised its price target for Phreesia to $11 while maintaining an Equal-Weight rating. This update places the firm's outlook within the broader analyst consensus, which currently averages $14.13. The stock remains well below its 52-week high of $24.07, reflecting a significant drop from previous levels.